Search Results - "KELSEN, D. P"

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis by Janjigian, Y.Y., Werner, D., Pauligk, C., Steinmetz, K., Kelsen, D.P., Jäger, E., Altmannsberger, H.M., Robinson, E., Tafe, L.J., Tang, L.H., Shah, M.A., Al-Batran, S.-E.

“…To determine whether human epidermal growth factor receptor 2 (HER2) status is an independent prognostic factor in metastatic gastric and gastroesophageal…”
Get full text

Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma by Fields, R C, Strong, V E, Gönen, M, Goodman, K A, Rizk, N P, Kelsen, D P, Ilson, D H, Tang, L H, Brennan, M F, Coit, D G, Shah, M A

“…Background: To characterise recurrence patterns and survival following pathologic complete response (pCR) in patients who received preoperative therapy for…”
Get full text

Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases by BRENNER, B, SHAH, M. A, GONEN, M, KLIMSTRA, D. S, SHIA, J, KELSEN, D. P

“…Small-cell carcinoma (SmCC) of the gastrointestinal tract is a very rare and aggressive malignancy. To better define its clinicopathological features, the…”
Get full text

Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer by Ilson, DH, Wadleigh, RG, Leichman, LP, Kelsen, DP

“…Background: The purpose of the study was to evaluate the efficacy of weekly paclitaxel (Taxol) in advanced esophageal cancer. Patients and methods: One hundred…”
Get full text

Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience by Ku, G.Y., Minsky, B.D., Rusch, V.W., Bains, M., Kelsen, D.P., Ilson, D.H.

“…Esophageal small-cell carcinoma (SCC) is rare, highly malignant and the optimal treatment approach has not been defined. We report the largest…”
Get full text

A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma by Duffy, A., Kortmansky, J., Schwartz, G. K., Capanu, M., Puleio, S., Minsky, B., Saltz, L., Kelsen, D. P., O'Reilly, E. M.

“…Purpose: To determine the maximum tolerated dose (MTD) of erlotinib when administered concurrently with twice weekly gemcitabine and radiation therapy (RT) for…”
Get full text

Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors by FORNIER, M. N, RATHKOPF, D, SHAH, M, PATIL, S, O'REILLY, E, TSE, A. N, HUDIS, C, LEFKOWITZ, R, KELSEN, D. P, SCHWARTZ, G. K

“…Purpose: Flavopiridol is a cyclin-dependent kinase inhibitor that enhances docetaxel-induced apoptosis in a sequence-specific manner. In vivo , docetaxel must…”
Get full text

Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer by Kelsen, David P, Ginsberg, Robert, Pajak, Thomas F, Sheahan, Daniel G, Gunderson, Leonard, Mortimer, Joanne, Estes, Norman, Haller, Daniel G, Ajani, Jaffer, Kocha, Walter, Minsky, Bruce D, Roth, Jack A

“…Esophageal carcinoma is an aggressive disease with a poor prognosis. For patients with stage 1, 2, or 3 carcinomas, surgery alone remains one standard of care…”
Get full text

A phase II trial of neoadjuvant cisplatin–fluorouracil followed by postoperative intraperitoneal floxuridine–leucovorin in patients with locally advanced gastric cancer by Brenner, B, Shah, MA, Karpeh, MS, Gonen, M, Brennan, MF, Coit, DG, Klimstra, DS, Tang, LH, Kelsen, DP

“…Background: The aim of the study was to evaluate the efficacy and toxicity of neoadjuvant chemotherapy with intravenous (i.v.) cisplatin and fluorouracil…”
Get full text

A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan by Sharma, S., Kemeny, N., Kelsen, D. P., Ilson, D., O’Reilly, E., Zaknoen, S., Baum, C., Statkevich, P., Hollywood, E., Zhu, Y., Saltz, L. B.

“…Background: ras genes encode Ras proteins that are important for signal transduction in cancer cells. Farnesyl protein transferase (FPTase) is an enzyme that…”
Get full text

Chemotherapy in esophageal cancer by Enzinger, P C, Ilson, D H, Kelsen, D P

“…The incidence of esophageal cancer continues to increase due to a rapid increase in adenocarcinoma of the distal esophagus and gastroesophageal junction. At…”
Get more information

Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face by Fata, Farid, O'Reilly, Eileen, Ilson, David, Pfister, David, Leffel, David, Kelsen, David P., Schwartz, Gary K., Casper, Ephraim S.

“…BACKGROUND Angiosarcomas are rare tumors. Based on a complete response observed in a patient with angiosarcoma of the scalp treated with paclitaxel in a Phase…”
Get full text

Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus by Ilson, D H, Ajani, J, Bhalla, K, Forastiere, A, Huang, Y, Patel, P, Martin, L, Donegan, J, Pazdur, R, Reed, C, Kelsen, D P

“…We have previously identified paclitaxel as an active single agent in the treatment of esophageal cancer. We performed a phase II trial of paclitaxel in…”
Get more information

Adjuvant and neoadjuvant therapy for gastric cancer by Kelsen, D P

“…In the United States and in Europe, curative resections are possible in only 50% to 60% of newly diagnosed gastric cancer patients chosen to undergo surgery…”
Get more information

Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal Cancer by ILSON, D. H, SALTZ, L, KELSEN, D. P, ENZINGER, P, YING HUANG, KORNBLITH, A, GOLLUB, M, O'REILLY, E, SCHWARTZ, G, DEGROFF, J, GONZALEZ, G

“…To evaluate the response, toxicity, survival, and quality of life in patients with unresectable or metastatic esophageal cancer treated with weekly irinotecan…”
Get full text

Systemic chemotherapy does not increase the risk of gastrointestinal perforation by Asmis, T.R., Capanu, M., Kelsen, D.P., Shah, M.A.

“…Gastrointestinal perforation is a rare complication of gastric cancer. Although there is the perception of chemotherapy aggravating the perforation risk, the…”
Get full text

Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells by SCHWARTZ, G. K, FARSI, K, MASLAK, P, KELSEN, D. P, SPRIGGS, D

“…Flavopiridol (L86-8275) is a synthetic flavone currently undergoing Phase I clinical trials. It is active against a series of human cancer cell lines and has…”
Get full text

Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals by Rice, T. W., Ishwaran, H., Hofstetter, W. L., Kelsen, D. P., Apperson‐Hansen, C., Blackstone, E. H., Chen, Ken N., Rice, Thomas W., Blackstone, Eugene H., Apperson‐Hansen, Carolyn, Wijnhoven, Bas P.L., van Lanschot, Jan, Lagarde, Sjoerd, Liu, Jun‐Feng, Scott, Walter J., Edmondson, Donna, Burger, Riette, Davies, Andrew R., Zylstra, Janine, Räsänen, Jari V., Salo, Jarmo A., Sundstrom, Yvonne, Pera, Manuel, D'Journo, Xavier B., Kesler, Kenneth A., Hofstetter, Wayne L., Correa, Arlene, Swisher, Stephen G., Allen, Mark S., Denlinger, Chad E., Rusch, Valerie W., Smithers, B. Mark, Gotley, David, Barbour, Andrew, Thomson, Iain, Griffin, S. Michael, Shenfine, Jon, Schipper, Paul H., Hunter, John G., Allum, William H., (Vincent) Fang, Wentao, Darling, Gail E., Lerut, Tony E.M.R., Nafteux, Phillipe R., van Hillegersberg, Richard, Cerfolio, Robert J., Durand, Luis, De Antón, Roberto, Ferguson, Mark K., Law, Simon, Orringer, Mark B., Marshall, Becky L., Duranceau, André, Howson, Susan, Luketich, James D., Pennathur, Arjun, Lovas, Kathy, Watson, Thomas J., Cecconello, Ivan, Chen, Long‐Qi

“…SUMMARY We report analytic and consensus processes that produced recommendations for pathologic stage groups (pTNM) of esophageal and esophagogastric junction…”
Get full text

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors by Saltz, L B, Kanowitz, J, Kemeny, N E, Schaaf, L, Spriggs, D, Staton, B A, Berkery, R, Steger, C, Eng, M, Dietz, A, Locker, P, Kelsen, D P

“…To determine the maximum-tolerable dose (MTD) of fluorouracil (5FU) when given with fixed doses of leucovorin and irinotecan (CPT-11), to define the…”
Get more information

Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer by Grann, A, Minsky, B D, Cohen, A M, Saltz, L, Guillem, J G, Paty, P B, Kelsen, D P, Kemeny, N, Ilson, D, Bass-Loeb, J

“…We report the downstaging, sphincter preservation, acute toxicity, and preliminary local control and survival results of preoperative 5-fluorouracil (5-FU),…”
Get more information